From the publishers of JADPRO

CAR T-Cell Therapy Resource Center

Advertisement
Interview With Linda Ramsdell, MSN, FNP-BC, OCN: Administering CAR T-Cell Therapy in the Outpatient Setting
0 seconds of 0 secondsVolume 90%
Press shift question mark to access a list of keyboard shortcuts
Keyboard Shortcuts
Play/PauseSPACE
Increase Volume↑
Decrease Volume↓
Seek Forward→
Seek Backward←
Captions On/Offc
Fullscreen/Exit Fullscreenf
Mute/Unmutem
Decrease Caption Size-
Increase Caption Size+ or =
Seek %0-9
00:00
00:00
00:00
 

Interview With Linda Ramsdell, MSN, FNP-BC, OCN: Administering CAR T-Cell Therapy in the Outpatient Setting

Last Updated: Tuesday, April 26, 2022

Advertisement
News & Literature Highlights

Blood Advances

Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma

Journal of Clinical Oncology

Comparison of standard-of-care idecabtagene vicleucel and ciltacabtagene autoleucel in relapsed/refractory multiple myeloma

Cancer Cell

Restoration of LAT activity improves CAR T cell sensitivity and persistence in response to antigen-low acute lymphoblastic leukemia

Pediatric Blood & Cancer

Neuropsychological functioning in pediatric patients with leukemia or lymphoma treated with CAR T-cell therapy: A retrospective chart review

Leukemia

Anti-CD19 CAR-T cell therapy for acquired hemophilia A

Brain

Current state and perspectives of CAR T-cell therapy in central nervous system diseases

Clinical Cancer Research

Phase I study of ROR1-specific CAR-T cells in advanced hematopoietic and epithelial malignancies

Blood

CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML

Oncogene

Preclinical application of a CD155 targeting chimeric antigen receptor T-cell therapy for digestive system cancers

Critical Reviews in Oncology/Hematology

Chimeric antigen receptor T cell immunotherapy for gynecological malignancies

Advertisement
Case Studies

Bloodless Medicine Management of a Patient Receiving CAR T-Cell Therapy

Transverse Myelitis With Paraplegia: An Atypical Manifestation of Neurotoxicity Following CAR T-Cell Therapy

CAR T-cell Infusion in an Outpatient Setting: An Ideal Option for Selected Patients When Available

Fast Facts

Fast Facts #12: BCMA Targets

Advertisement
Quizzes
Test Your Knowledge of Bloodless Medicine Management of a Patient Receiving CAR T-Cell Therapy
Test your knowledge of atypical manifestation of neurotoxicity following CAR T-cell therapy
Test your knowledge of CAR T-cell therapy